49 completed. 49 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 49 | Completed 49 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 4 | Completed 4 |
Follow Diabetic Nephropathy: new trials by email Literature Review of Diabetic Nephropathy trials Research Report on Diabetic Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy Nidufexor, Placebo, Standard of Care (SoC) - Diabetic Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 83 | 2018-12-17 | 2022-08-10 |
| An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy MT-3995 Low, MT-3995 Middle, MT-3995 High - Diabetic Nephropathy | Phase 2 | Completed | Tanabe Pharma Corporation | 241 | 2016-02-01 | 2017-09-18 |
| Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy MT-3995 Low, MT-3995 Middle, MT-3995 High - Diabetic Nephropathy | Phase 2 | Completed | Tanabe Pharma Corporation | 293 | 2015-07-01 | 2017-03-03 |
| A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria CS-3150, placebo - Diabetic Nephropathy | Phase 2 | Completed | Daiichi Sankyo | 365 | 2015-01-01 | 2018-12-21 |
| Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients VPI-2690B low dose, VPI-2690B medium dose, Placebo to match VPI-2690B - Diabetic Nephropathy | Phase 2 | Completed | Vascular Pharmaceuticals, Inc. | 165 | 2014-09-01 | 2017-03-28 |
| Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy MT-3995, Placebo - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Tanabe Pharma Corporation | 31 | 2014-07-01 | 2015-09-16 |
| Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria Spironolactone, Placebo, Standard care - Diabetic Nephropathy, Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | Peter Rossing | 1777 | 2014-03-01 | 2018-12-21 |
| Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy. Green tea extract - Diabetic Nephropathy, Hypertension | Phase 2 | Completed | University of Campinas, Brazil | 50 | 2013-11-01 | 2016-08-04 |
| To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy DW1029M 600mg, DW1029M 1200mg, Placebo - Diabetic Nephropathy | Phase 2 | Completed | Dong Wha Pharmaceutical Co. Ltd. | 158 | 2013-10-01 | 2017-02-17 |
| Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy MT-3995-Low, MT-3995-High, Placebo - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Tanabe Pharma Corporation | 51 | 2013-07-01 | 2015-01-27 |
| Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy Mesenchymal Precursor Cells (MPCs) - Diabetic Nephropathy, Type 2 Diabetes | Phase 1 / Phase 2 | Completed | Mesoblast, Ltd. | 30 | 2013-07-01 | 2016-10-14 |
| Study of LY3016859 in Participants With Diabetic Nephropathy Placebo, LY3016859 - Diabetic Nephropathy | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 60 | 2013-03-01 | 2019-09-19 |
| A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy PF-04634817, Placebo - Diabetic Nephropathy | Phase 2 | Completed | Pfizer | 226 | 2012-12-01 | 2015-10-21 |
| A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR MT-3995 Low, MT-3995 High, Placebo - Diabetic Nephropathy | Phase 2 | Completed | Tanabe Pharma Corporation | 49 | 2012-12-01 | 2015-02-09 |
| A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria MT-3995 Low, MT-3995 High, Placebo - Diabetic Nephropathy | Phase 2 | Completed | Tanabe Pharma Corporation | 67 | 2012-11-01 | 2015-02-09 |
| Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Probucol 250mg/day, Probucol 500mg/day, Placebo - Diabetic Nephropathy | Phase 2 | Completed | Korea Otsuka Pharmaceutical Co., Ltd. | 126 | 2012-10-01 | 2017-05-03 |
| Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients Repository Corticotropin Injection, Placebo - Diabetic Nephropathy | Phase 2 | Completed | Mallinckrodt | 34 | 2012-05-01 | 2019-11-18 |
| The Effects of Sevelamer Carbonate on Diabetic Nephropathy Sevelamer Carbonate, calcium carbonate - Diabetic Nephropathy | Phase 2 | Completed | Gary Striker | 117 | 2012-02-01 | 2014-04-09 |
| A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Placebo, CCX140-B - Diabetic Nephropathy, Type 2 Diabetes Mellitus | Phase 2 | Completed | Amgen | 332 | 2011-10-01 | 2025-02-27 |
| Vitamin D Supplementation in Diabetic Nephropathy Vitamin D3 - Sub-optimal Vitamin D Status, Bone Disease | Phase 2 | Completed | University of Alberta | 120 | 2011-10-01 | 2022-08-31 |
Showing 20 of 49. Sign in to see all of them.
Diabetic Nephropathies (49) · Diabetes Mellitus (9) · Proteinuria (9) · Renal Insufficiency, Chronic (9) · Diabetes Mellitus, Type 2 (8) · Kidney Diseases (6) · Albuminuria (4) · Hypertension (2) · Bone Diseases (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Retinopathy (1) · Essential Hypertension (1) · Glomerulonephritis (1) · Metabolic Diseases (1) · Nephrotic Syndrome (1)
Diabetes Complications (49) · Endocrine System Diseases (49) · Female Urogenital Diseases (49) · Female Urogenital Diseases and Pregnancy Complications (49) · Male Urogenital Diseases (49) · Urogenital Diseases (49) · Urologic Diseases (49) · Kidney Diseases (43) · Diabetes Mellitus (40) · Pathological Conditions, Signs and Symptoms (18) · Glucose Metabolism Disorders (17) · Nutritional and Metabolic Diseases (17) · Metabolic Diseases (16) · Signs and Symptoms (13) · Urination Disorders (13)
Atrasentan (4) · pyridoxamine dihydrochloride (3) · CCX140-B (2) · Spironolactone (2) · Standard of Care (2) · bardoxolone methyl (2) · 2-(3-chlorophenylamino)phenylacetic acid (1) · Acetylcysteine (1) · Adrenocorticotropic Hormone (1) · Calcium Carbonate (1) · Capsules (1) · Captopril (1) · Cholecalciferol (1) · Eplerenone (1) · Fosinopril (1)
Tanabe Pharma Corporation (6) · AbbVie (prior sponsor, Abbott) (4) · Shiraz University of Medical Sciences (3) · Amgen (2) · BioStratum (2) · Biogen (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Abbott (1) · Aziende Chimiche Riunite Angelini Francesco S.p.A (1) · Chromaderm, Inc. (1) · Daiichi Sankyo (1) · Daiichi Sankyo Co., Ltd. (1) · Dong Wha Pharmaceutical Co. Ltd. (1) · Eli Lilly and Company (1)
United States (19) · Japan (8) · Germany (6) · Canada (5) · Italy (5) · Netherlands (5) · Puerto Rico (5) · Czechia (4) · Iran (4) · Poland (4) · Romania (4) · Spain (4) · Australia (3) · Bulgaria (3) · Greece (3)
Blai Coll, MD (2) · Jamshid Roozbeh, MD (2) · Masaomi Nangaku, Professor (2) · Paolo Fanti, MD (2) · Thorsten P Degenhardt, Ph.D. (2) · Adriaan Kooy, MD (1) · Alberto Ortiz, MD (1) · Alireza Esteghamati, M.D. (1) · Amin Banihashemi (1) · Andreas Birkenfeld, MD (1) · Christian Delles, MD (1)
PMID 33107592, PMID 28756065, PMID 23986513, PMID 32974732, PMID 37916745, PMID 18525041, PMID 20693353, PMID 21055801, PMID 21699484, PMID 22461535, PMID 22770926, PMID 23333585, PMID 23787544, PMID 23804455, PMID 24722445, PMID 25899538, PMID 26153128, PMID 26235932, PMID 26268910, PMID 26896310, PMID 26936907, PMID 27302208, PMID 27320846, PMID 27493100, PMID 27743903, PMID 29781558, PMID 32135136, PMID 33782940, PMID 36841085, PMID 37716952, PMID 39990662, PMID 40576086, PMID 41805697
2018 (1), R01DK063017 (1), R21AT004490 (1)